Clinical Research Directory
Browse clinical research sites, groups, and studies.
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Sponsor: Frantz Viral Therapeutics, LLC
Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Official title: A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)
Key Details
Gender
FEMALE
Age Range
25 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2020-09-09
Completion Date
2026-12-31
Last Updated
2025-10-02
Healthy Volunteers
No
Interventions
Artesunate vaginal insert
Artesunate formulated as vaginal inserts, 200mg
Placebo vaginal insert
Placebo for artesunate vaginal inserts
Locations (7)
Florida Gynecologic Oncology
Fort Myers, Florida, United States
University of Michigan
Ann Arbor, Michigan, United States
Cleveland Clinic Fairview Hospital
Cleveland, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Hillcrest Hospital
Mayfield Heights, Ohio, United States
The Harris Health System (L.B.J Hospital)
Houston, Texas, United States
University of Texas, M.D. Anderson
Houston, Texas, United States